Life Sciences

16 May 2019

PolyProx – Parkwalk UCEF VI investment

By |May 16th, 2019|

Parkwalk are delighted to welcome PolyProx to its portfolio following an investment from the University of Cambridge Enterprise Fund VI.

PolyProx Therapeutics is a biotechnology company focused on the discovery and development of a new class of drugs, Polyproxin™ molecules, to treat cancer and neurodegenerative diseases. Polyproxin™ molecules are biopharmaceuticals that selectively target disease-causing proteins […]

30 April 2019

Congenica – Congenica Raises £23.3M ($30.1M) for Series B Funding Round

By |April 30th, 2019|

Congenica, the global clinical decision support platform provider, today announced it has raised a further £13.25 ($17.1) million in additional equity investment, led by Parkwalk Advisors. The round attracted new strategic investors, including Digital China Health Technologies Corporation Limited (DCHealth), alongside follow-on funding from existing investors. The total amount raised across its B round financings […]

12 March 2019

PredictImmune – announce formal entry of PredictSURE IBD™ into the NICE Diagnostic Assessment Programme

By |March 12th, 2019|

PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today announced the formal entry of its first product, PredictSURE IBD™, into NICE’s Diagnostic Assessment Programme (DAP).

The DAP evaluates new, cutting-edge medical diagnostic technologies, producing guidance to help people working in the NHS make efficient, cost-effective and […]

25 February 2019

Petmedix – Parkwalk’s latest investment

By |February 25th, 2019|

Parkwalk are delighted to announces its investment in Petmedix. The Cambridge based pet therapeutics company raises £8M Series A funding, with Parkwalk co-investing alongside Digitalis Ventures. Parkwalk were attracted by the team and the market potential.

PetMedix is applying 30 years of antibody research and the scientific work of two of its founders, Professor Allan Bradley […]

12 December 2018

Istesso – Parkwalk investment

By |December 12th, 2018|

Parkwalk are delighted to welcome Istesso to its portfolio following an investment from the Parkwalk Opportunities EIS Fund.

Istesso is a drug development company working in the field of immunometabolism. It’s pre-clinical and clinical assets work by reprogramming cellular metabolism and have applications in autoimmune conditions. Istesso’s lead drug, MBS2320, is in a Phase 2a […]

20 October 2018

DefiniGEN – Parkwalk closes follow on investment

By |October 20th, 2018|

Parkwalk closes DefiniGen investment.

DefiniGEN, a spin-out from the University of Cambridge Regenerative Medicine Department at Addenbrooke’s Hospital, have created a stem cell technology to provide human cells to the drug discovery sector for use in lead optimisation and toxicity programmes.

The Company’s proprietary production platform OptiDIFF robustly generates human cell types including using hIPSC human […]

Congenica – earns major role in supporting world’s first routine national genomic medicine service

By |October 17th, 2018|

Genomics England names Congenica as its Clinical Decision Support Service partner for the delivery of the NHS Genomic Medicine Service

Cambridge, United Kingdom – 17 October, 2018 – Congenica has been awarded a multi-year contract by Genomics England, to be a provider of Diagnostic Decision Support Services for them to deliver for the world leading NHS Genomic […]

Vitamica – University of Bristol Enterprise Fund II investment

By |October 9th, 2018|

We are delighted to announce that the University of Bristol Enterprise Fund II, managed by Parkwalk, has invested in Vitamica, a University of Bristol spin-out that aims to exploit a novel approach for determining the susceptibility of bacteria to antibiotics.

Resistance of bacteria to antibiotics is an increasing problem across the world, resulting in poorer healthcare […]

17 September 2018

Exonate – University of Bristol Enterprise Fund II investment

By |September 17th, 2018|

We are delighted to announce that the University of Bristol Enterprise Fund II, managed by Parkwalk, has invested in Exonate.

Exonate are developing a novel approach to modulating new vessel growth.  By controlling the balance of two contrasting forms of a protein called Vascular Endothelial Growth Factor (VEGF), they have demonstrated that they could not only treat models […]

10 August 2018

Astellas announces acquisition of Quethera

By |August 10th, 2018|

Astellas Pharma Inc. and Quethera Limited announced that Astellas has acquired Quethera, a gene therapy company headquartered in the United Kingdom that is focused on developing novel treatments for ocular disorders, such as glaucoma.

Through this transaction, Astellas has acquired Quethera’s ophthalmic gene therapy program, which uses a recombinant adeno-associated viral vector system (rAAV) to introduce […]

3 April 2018

Micrima – University of Bristol Enterprise Fund II investment

By |April 3rd, 2018|

We are delighted to announce that the University of Bristol Enterprise Fund II, managed by Parkwalk, has invested in Micrima.

Micrima is a Bristol based diagnostic imaging company, developing a new Breast Imaging System (MARIA) aimed at radically improving breast cancer detection and survival rates through the provision of much safer, more frequent, more comfortable and […]

20 February 2018

OxSyBio – Parkwalk closes Investment

By |February 20th, 2018|

We are delighted to announce that Parkwalk has participated in the funding of OxSyBio, which is seeking to commercialise IP generated by Professor Hagan Bayley at the University of Oxford.

The company has the unique ability to 3D print materials that have function derived from biology, but which are not living. The company is also able to print […]

6 November 2017

Parkwalk and UCEF III close NeoPhore investment

By |November 6th, 2017|

We are pleased to announce that the University of Cambridge Enterprise Fund III, managed by Parkwalk, and Parkwalk funds have made an investment in NeoPhore, a PhoreMost Ltd spinout, alongside the Cancer Research Technology Pioneer Fund and the University of Cambridge. NeoPhore’s mission is to develop novel small molecule therapies to treat cancer by […]

Parkwalk and UOIF III close MoA investment

By |November 2nd, 2017|

We are pleased to announce that the University of Oxford Innovation Fund III, managed by Parkwalk, and the Parkwalk Opportunities EIS Fund have made an investment in MoA Technology, a plant genetics spin-out from the University of Oxford.

13 September 2017

PsyOmics – follow-on investment

By |September 13th, 2017|

We are delighted to announce that the University of Cambridge Enterprise Fund V and the Parkwalk Opportunities Fund have invested in a follow-on financing round in PsyOmics, a spin-out from the Department of Chemical Engineering and Biotechnology.

The company aims to utilise blood-based diagnostics to increase the speed of diagnosis and to reduce misdiagnosis for […]

19 May 2017

Horizon Discovery – Parkwalk UCEF I exit

By |May 19th, 2017|

We are delighted to have generated a 2.36x return (3.37x inclusive of initial tax reliefs) for our investors on the sale of the University of Cambridge Enterprise Fund I holding in Horizon Discovery plc. The investment was held for 3.9 years and the exit was generated through a single block trade.
We would like to thank […]

Predictimmune – Parkwalk closes investment

By |May 16th, 2017|

We are delighted to announce that the Parkwalk Opportunities Fund and the University of Cambridge Enterprise Fund IV have completed an investment in Predictimmune Limited, a spinout company from the University of Cambridge.
Predictimmune is developing prognostic tests for immune-mediated conditions to aid their management and improve patient outcomes. Their first offering, PredictImmune-CD, will be […]

8 April 2017

Azul Optics – University of Bristol Enterprise Fund I investment

By |April 8th, 2017|

We are delighted to announce that the University of Bristol Enterprise Fund I, managed by Parkwalk, has invested in Azul Optics.

Azul Optics is developing a device that can rapidly assess macular pigment density. The device will be affordable, fast, easy-to-use and compact, making it easy to integrate macular pigment density screening into regular eye exams. […]

Sphere Fluidics accepted onto the London Mayor’s International Business “Go to Grow” Programme to assist with business scaling.

By |April 4th, 2017|

28 February 2017

Parkwalk closes PhoreMost follow-on investment

By |February 28th, 2017|

We are pleased to announce that Parkwalk has made an investment in Phoremost, a Cambridge University spinout, as part of a Series ‘B’ round of equity funding, alongside Amadeus Capital Partners and the University. Phoremost’s mission is to accelerate, diversify and rationalise drug discovery.

PhoreMost has developed a next-generation phenotypic screening platform called ‘SiteSeeker’ to identify […]